Title: Status of liver fibrosis evaluated by aspartate aminotransferase to platelet ratio in patients with non-alcoholic fatty liver disease
Abstract: Objective
To evaluate the prevalence and risk factors of progressive liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD).
Methods
A total of 2 054 subjects who underwent health check up and were diagnosed as NAFLD in 9 institutions were included in the study. Blood routine and biochemical findings were collected to calculate aspartate aminotransferase-to-platelet ratio index (APRI). Subjects were divided into three groups according to diagnostic threshold of liver fibrosis: APRI<0.43 group, APRI 0.43-0.53 group and APRI≥0.54 group. The correlation between APRI and biochemical variables was analyzed, and the risk factors of progressive fibrosis were also analyzed.
Results
Among 2 054 subjects (male/female 1 598/456) there were 61 cases with APRI≥0.98 (2.97%, progressive fibrosis), 318 with APRI≥0.54 (15.48%), 1 475 with APRI<0.43 (71.81%), 261 with APRI 0.43-0.53 (12.71%). Logistic stepwise regression analysis showed that TG(P=0.002, OR=1.095, 95%CI : 1.033-1.161), 2 hPG(P=0.000, OR=1.103, 95%CI : 1.058-1.151, BUN(P=0.034, OR=1.215, 95%CI: 1.014-1.454) were risk factors, and HDL-C(P=0.034, OR=0.353, 95%CI: 0.135-0.924) was a protective factor for the progression of fibrosis.
Conclusion
The progressive fibrosis in patients with NAFLD is closely associated to blood glucose and lipid metabolism disorder.
Key words:
Fatty liver; Diagnosis; Aspartate aminotransferase-to-platelet ratio index; Fibrosis
Publication Year: 2017
Publication Date: 2017-03-04
Language: en
Type: article
Access and Citation
Cited By Count: 1
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot